Non-Small Cell Lung Cancer Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Therapy (Target Therapy, Immunotherapy, Chemotherapy); Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)

Report Code: TIPRE00013508 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

About 80% to 85% of lung cancers are NSCLC. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as NSCLC because their treatment and prognoses (outlook) are often similar.

MARKET DYNAMICS

The non-small cell lung cancer therapeutics market is driving due to the increasing patient population, expected entry of several drugs, and rising investment by industry players in R&D of NSCLC therapy. However, pricing pressure may impede the growth.

MARKET SCOPE

The "Non-Small Cell Lung Cancer Therapeutics Market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of non-small cell lung cancer therapeutics market with detailed market segmentation by therapy and cancer type. The non-small cell lung cancer therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in non-small cell lung cancer therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The non-small cell lung cancer therapeutics market is segmented on the basis by therapy and cancer type. On the basis of therapy, the market is categorized as target therapy, immunotherapy, and chemotherapy. On the basis of cancer type, the market is categorized as adenocarcinoma, squamous cell carcinoma and large cell carcinoma.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the non-small cell lung cancer therapeutics market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The non-small cell lung cancer therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting non-small cell lung cancer therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors affecting the non-small cell lung cancer therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the non-small cell lung cancer therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from non-small cell lung cancer therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for non-small cell lung cancer therapeutics in the global market. Below mentioned is the list of few companies engaged in the non-small cell lung cancer therapeutics market.

The report also includes the profiles of key players in non-small cell lung cancer therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  GlaxoSmithKline plc
  •  Novartis
  •  AstraZeneca
  •  Eli Lilly and Company
  •  Pfizer Inc.
  •  F. Hoffmann-La Roche Ltd
  •  Bristol-Myers Squibb
  •  Takeda
  •  Merck Sharp
  •  Boehringer Ingelheim

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Non-Small Cell Lung Cancer Therapeutics Market - By Therapy
1.3.2 Non-Small Cell Lung Cancer Therapeutics Market - By Cancer Type
1.3.3 Non-Small Cell Lung Cancer Therapeutics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. NON-SMALL CELL LUNG CANCER THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. NON-SMALL CELL LUNG CANCER THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - THERAPY
7.1. OVERVIEW
7.2. THERAPY MARKET FORECASTS AND ANALYSIS
7.3. TARGET THERAPY
7.3.1. Overview
7.3.2. Target Therapy Market Forecast and Analysis
7.4. IMMUNOTHERAPY
7.4.1. Overview
7.4.2. Immunotherapy Market Forecast and Analysis
7.5. CHEMOTHERAPY
7.5.1. Overview
7.5.2. Chemotherapy Market Forecast and Analysis
8. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2027 - CANCER TYPE
8.1. OVERVIEW
8.2. CANCER TYPE MARKET FORECASTS AND ANALYSIS
8.3. ADENOCARCINOMA
8.3.1. Overview
8.3.2. Adenocarcinoma Market Forecast and Analysis
8.4. SQUAMOUS CELL CARCINOMA
8.4.1. Overview
8.4.2. Squamous Cell Carcinoma Market Forecast and Analysis
8.5. LARGE CELL CARCINOMA
8.5.1. Overview
8.5.2. Large Cell Carcinoma Market Forecast and Analysis
9. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Non-Small Cell Lung Cancer Therapeutics Market Overview
9.1.2 North America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis
9.1.3 North America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Therapy
9.1.4 North America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Cancer Type
9.1.5 North America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Non-Small Cell Lung Cancer Therapeutics Market
9.1.5.1.1 United States Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.1.5.1.2 United States Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.1.5.2 Canada Non-Small Cell Lung Cancer Therapeutics Market
9.1.5.2.1 Canada Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.1.5.2.2 Canada Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.1.5.3 Mexico Non-Small Cell Lung Cancer Therapeutics Market
9.1.5.3.1 Mexico Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.1.5.3.2 Mexico Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.2. EUROPE
9.2.1 Europe Non-Small Cell Lung Cancer Therapeutics Market Overview
9.2.2 Europe Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis
9.2.3 Europe Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Therapy
9.2.4 Europe Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Cancer Type
9.2.5 Europe Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Non-Small Cell Lung Cancer Therapeutics Market
9.2.5.1.1 Germany Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.2.5.1.2 Germany Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.2.5.2 France Non-Small Cell Lung Cancer Therapeutics Market
9.2.5.2.1 France Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.2.5.2.2 France Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.2.5.3 Italy Non-Small Cell Lung Cancer Therapeutics Market
9.2.5.3.1 Italy Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.2.5.3.2 Italy Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.2.5.4 Spain Non-Small Cell Lung Cancer Therapeutics Market
9.2.5.4.1 Spain Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.2.5.4.2 Spain Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.2.5.5 United Kingdom Non-Small Cell Lung Cancer Therapeutics Market
9.2.5.5.1 United Kingdom Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.2.5.5.2 United Kingdom Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Market Overview
9.3.2 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis
9.3.3 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Therapy
9.3.4 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Cancer Type
9.3.5 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Non-Small Cell Lung Cancer Therapeutics Market
9.3.5.1.1 Australia Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.3.5.1.2 Australia Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.3.5.2 China Non-Small Cell Lung Cancer Therapeutics Market
9.3.5.2.1 China Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.3.5.2.2 China Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.3.5.3 India Non-Small Cell Lung Cancer Therapeutics Market
9.3.5.3.1 India Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.3.5.3.2 India Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.3.5.4 Japan Non-Small Cell Lung Cancer Therapeutics Market
9.3.5.4.1 Japan Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.3.5.4.2 Japan Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.3.5.5 South Korea Non-Small Cell Lung Cancer Therapeutics Market
9.3.5.5.1 South Korea Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.3.5.5.2 South Korea Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Market Overview
9.4.2 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis
9.4.3 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Therapy
9.4.4 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Cancer Type
9.4.5 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Non-Small Cell Lung Cancer Therapeutics Market
9.4.5.1.1 South Africa Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.4.5.1.2 South Africa Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.4.5.2 Saudi Arabia Non-Small Cell Lung Cancer Therapeutics Market
9.4.5.2.1 Saudi Arabia Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.4.5.2.2 Saudi Arabia Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.4.5.3 U.A.E Non-Small Cell Lung Cancer Therapeutics Market
9.4.5.3.1 U.A.E Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.4.5.3.2 U.A.E Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Non-Small Cell Lung Cancer Therapeutics Market Overview
9.5.2 South and Central America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis
9.5.3 South and Central America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Therapy
9.5.4 South and Central America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Cancer Type
9.5.5 South and Central America Non-Small Cell Lung Cancer Therapeutics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Non-Small Cell Lung Cancer Therapeutics Market
9.5.5.1.1 Brazil Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.5.5.1.2 Brazil Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
9.5.5.2 Argentina Non-Small Cell Lung Cancer Therapeutics Market
9.5.5.2.1 Argentina Non-Small Cell Lung Cancer Therapeutics Market by Therapy
9.5.5.2.2 Argentina Non-Small Cell Lung Cancer Therapeutics Market by Cancer Type
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ASTRAZENECA
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ELI LILLY AND COMPANY
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. PFIZER INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. F. HOFFMANN-LA ROCHE LTD
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BRISTOL-MYERS SQUIBB
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. TAKEDA
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. MERCK SHARP
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. BOEHRINGER INGELHEIM
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11.
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. GlaxoSmithKline plc
2. Novartis
3. AstraZeneca
4. Eli Lilly and Company
5. Pfizer Inc.
6. F. Hoffmann-La Roche Ltd
7. Bristol-Myers Squibb
8. Takeda
9. Merck Sharp
10. Boehringer Ingelheim

TIPRE00013508
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking